Therapeutic Angiogenesis

Gene Therapy to Stimulate Blood Vessel Growth in Coronary Arteries to be Tested

Published in Gene Therapy Weekly, January 11th, 2001

The University of Pittsburgh Medical Center (UPMC) in Pennsylvania is one of six centers participating in a Genzyme Surgical Products-sponsored clinical trial of a proprietary gene therapy designed to promote the growth of new blood vessels from existing blood vessels around blocked coronary arteries.

The Phase I study will evaluate the safety and efficacy of a gene therapy based on an engineered form of the gene known as hypoxia inducible factor 1 alpha (HIF-1), which has been shown in laboratory studies to turn on the expression of many proteins associated with the natural process of blood vessel formation called angiogenesis.

While angiogenesis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry